Author

Jan Krönke

German Cancer Research CenterORCID 0000-0002-4649-0506Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 2 Organism:human· 2 Assay:proteomics· 2 Research Focus:clustering· 1 Approach:deep learning· 1 Research Focus:differential expression· 1 Assay:DNA methylation· 1 Research Focus:drug response / drug discovery· 1

Frequent Co-Authors

Philipp MertinsiD· 2 shared Aarthi Nivasini MaheshiD· 1 shared Ahmed M. MamdouhiD· 1 shared Alexandre PuissantiD· 1 shared Benedikt ObermayeriD· 1 shared Brandon Douglas BrowniD· 1 shared Camille LobryiD· 1 shared Cheryl Gek Teng Chan· 1 shared

Activity by Year

2025-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 31 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

Philipp MertinsORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Cancer BiologybioRxivPreprintAug 21, 2026

Translating multi-omics complexity into sparse prognostic biomarkers for multiple myeloma

Benedikt Obermayer, Manuela Benary, Jan Krönke…·Dieter Beule

This paper identifies prognostic biomarkers for multiple myeloma by integrating multi-omics data and shows that proteomic features outperform genomic or transcriptomic data in classification.

DOI 10.64898/2026.08.21.746155

humanbulk RNA-seq

𝕏 PostBluesky

Cancer BiologybioRxivPreprintMay 17, 2025

BIRC5 dependency defines a targetable vulnerability in TP53 mutant acute myeloid leukemia

Ahmed M. Mamdouh, Fang Qi Lim, Yang Mi…·Shruti Bhatt

This study identifies BIRC5 as a targetable vulnerability in TP53 mutant AML, showing that survivin/IAP inhibitors can overcome therapy resistance.

2 citations

humanbulk RNA-seq

𝕏 PostBluesky